(AOF) – Carmat, a medtech specialist in artificial hearts, continues the dynamic of its implementations in the EFICAS study and reiterates its confidence in its 2024 prospects. Stéphane Piat, Managing Director declares: “I am very satisfied with the progress of this study , both on the rate of inclusions and on the results observed to date. With 20 patients implanted, we have already carried out 38% of the planned inclusions (out of 52 in total), which once again demonstrates the very strong interest of French doctors and hospitals in the Aeson heart.
Building on the clinical results of the EFICAS study, the progression of implementations over the first 4 months of 2024, and its solid base of 39 hospitals trained in commercial implementations, the company reiterates its turnover forecast of the order of 14 million euros for 2024.
Taking into account its cash position and its “business plan”, the Company’s financial horizon currently extends to the end of May 2024, and CARMAT estimates its 12-month financing requirement at approximately 45 million euros.
“The company is working very actively on strengthening its equity capital with the participation, already confirmed, of some of its key shareholders, allowing it to extend its financial horizon in the short term,” indicates a press release from Carmat.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
